alvimopan Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
143 156053-89-3

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • alvimopan dihydrate
  • alvimopan anhydrous
  • LY246736
  • LY-246736
  • alvimopan
  • entereg
mu opioid receptor antagonist; intended to treat constipation in patients taking opiates for pain
  • Molecular weight: 424.54
  • Formula: C25H32N2O4
  • CLOGP: 2.16
  • LIPINSKI: 0
  • HAC: 6
  • HDO: 3
  • TPSA: 89.87
  • ALOGS: -4.71
  • ROTB: 8

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 3 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 0.10 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 2 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.81 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 6 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 0.43 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 5.84 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.20 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 5.30 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
May 20, 2008 FDA CUBIST PHARMS

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

Pharmacologic Action:

SourceCodeDescription
ATC A06AH02 ALIMENTARY TRACT AND METABOLISM
DRUGS FOR CONSTIPATION
DRUGS FOR CONSTIPATION
Peripheral opioid receptor antagonists
FDA MoA N0000000154 Opioid Antagonists
FDA EPC N0000175691 Opioid Antagonist
MeSH PA D005765 Gastrointestinal Agents

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Postoperative ileus indication 235833007
Myocardial infarction contraindication 22298006 DOID:5844
Hepatic failure contraindication 59927004
Chronic renal failure syndrome contraindication 90688005

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 3.38 acidic
pKa2 9.82 acidic
pKa3 9.22 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Mu-type opioid receptor GPCR ANTAGONIST Ki 9.40 WOMBAT-PK CHEMBL
Kappa-type opioid receptor GPCR Ki 7 CHEMBL
Delta-type opioid receptor GPCR Ki 7.92 CHEMBL

External reference:

IDSource
677C126AET UNII
4025232 VUID
N0000179783 NUI
D02878 KEGG_DRUG
170098-38-1 SECONDARY_CAS_RN
C1508750 UMLSCUI
CHEBI:135686 CHEBI
CHEMBL270190 ChEMBL_ID
DB06274 DRUGBANK_ID
5488548 PUBCHEM_CID
8245 INN_ID
C419502 MESH_SUPPLEMENTAL_RECORD_UI
7471 IUPHAR_LIGAND_ID
1516803 RXNORM
136917 MMSL
25351 MMSL
341264 MMSL
d07141 MMSL
012792 NDDF
437886007 SNOMEDCT_US
437917007 SNOMEDCT_US
4025232 VANDF

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Alvimopan HUMAN PRESCRIPTION DRUG LABEL 1 0591-2312 CAPSULE 12 mg ORAL ANDA 26 sections
Entereg HUMAN PRESCRIPTION DRUG LABEL 1 67919-020 CAPSULE 12 mg ORAL NDA 29 sections